Ironshore Pharmaceuticals & Development, Inc.

University of Texas System

Auxilium US Holdings, LLC

Pharmalyte Solutions, LLC

Purdue Research Foundation

Epicept Corporation

Phoenix Biotechnology, Inc.

Auxilium International Holdings, Inc.

Feng Zhang

David Lickrish

John Joseph Koleng, Jr

Michael Crowley

Justin M Keen

James William McGinity

Stephen F Brandon

Stuart Schoenherr

Robert O Williams, Iii

Michael J McGinity

John R Floyd

Joerg Appenzeller

Yuqi Zhu

Otis Crandell Addington

Gavril W Pasternak

Albert V Davydov

Leonid A Bendersky

Yuri Kolesnikov

Sergiy Krylyuk

James W Mcginity

Siyuan Huang

Abbe Miller

Huairuo Zhang

Crandell Addington

Michael M Crowley

Michael W Crowley

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Compositions for treatment of attention deficit hyperactivity disorder

Compositions and methods of preparing amorphous drug formulations through hot melt extrusion which result in decreased decomposition of the desired drug are provided herein. Also provided are methods and compositions which further comprise a pharmaceutically acceptable thermoplastic polymer. In some embodiments, these compositions comprise a therapeutically active agent which is only sparingly soluble in water.

Methods of preparing extrudates

The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.

Implant compositions for the unidirectional delivery of therapeutic compounds to the brain

A method of switching a phase-change device (Device), including changing phase of the Device from a semiconducting 2H phase to a new 2Hphase with a higher conductivity, the Device having an active material with a thickness including a phase transition material to thereby transition the Device from a high resistive state (HRS) to a low resistive state (LRS) by application of a set voltage and further to return the Device from the LRS back to the HRS by application of a reset voltage.

Phase transition based resistive random-access memory

A resistive random access memory (Device) is disclosed. The Device includes a substrate, a first electrode formed atop the substrate, a tunneling barrier layer formed atop the first electrode, an active material formed atop the tunneling barrier layer, an isolation layer formed atop the active material, and a second electrode formed atop the isolation layer, the first electrode and the second electrode provide electrical connectivity to external components, where the active material is a phase change material which undergoes phase transition in the presence of an electric field, Joule heating, or a combination thereof.

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.

Methods of treatment of attention deficit hyperactivity disorder

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.

Growing community of inventors

Pflugerville, TX, United States of America

Feng Zhang